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ABSTRACT
Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD).
The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14
mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and
relapsed HD. One hundred twenty-seven patients with a median age of 33 years (range, 14-67 years)
underwent transplantation. The regimen was well tolerated, with 5.5% treatment-related mortality at 100 days
after transplantation. With a median follow up of 6.7 years, the 5-year progression-free survival was 48  5%,
and the 5-year overall survival was 51  5%. A Cox proportional hazards model identified refractory disease at
time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk
>10 cm affected overall survival. Five patients died between 5.3 and 9.3 years of late complications, including
secondary myelodysplasia or acute myeloid leukemia, secondary solid malignancies, and pulmonary toxicity.
This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the
control of HD and with a low-risk of early treatment-related mortality.
© 2006 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Hodgkin disease (HD) is a chemosensitive disease,
ith 50%-60% of patients cured with conventional
hemotherapy and radiation [1,2]. However, only a
mall proportion of patients who do not achieve com-
lete remission or relapse after induction chemother-
py is cured with standard salvage chemotherapy [3].
or these patients, high-dose chemotherapy followed
y autologous stem cell transplantation (ASCT) can
mprove outcome [4-9]. Although several preparative
egimens with or without total body irradiation (TBI)
ave been investigated in HD, no superiority of a
ingle regimen has been established [10,11]. In partic- ilar, only 1 study investigated the efﬁcacy of high-
ose busulfan (Bu)-based regimens speciﬁcally in pa-
ients with HD [12]. Bu-based preparative regimens
ave been extensively examined and shown to be ef-
ective in ASCT and allogeneic transplantation for a
ide variety of other hematologic disorders including
cute and chronic leukemias and non-Hodgkin lym-
homa (NHL) [13-22].
We previously reported our experience with Bu-
ased preparative regimens in myeloid disorders and
HL [14,16,20]. The initial study with Bu 16 mg/kg
nd cyclophosphamide (Cy) 120 mg/kg (BuCy2) was
riginally evaluated but was associated with a high
ncidence of severe hepatic veno-occlusive disease and
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N. Wadehra et al.1344reatment-related mortality (TRM) [14]. The BuCy2
egimen was subsequently revised in NHL to lower
he dose of Bu from 16 to 14 mg/kg to decrease severe
eno-occlusive disease and TRM. In addition, etopo-
ide was added to improve effectiveness without in-
reasing toxicity substantially. Using this regimen in
HL, 382 patients were treated with Bu, Cy, and
toposide at doses comparable to those used in our
D patient population. It was found to be effective,
ith a 46.9% progression-free survival (PFS) and a
.6% TRM [20]. The Fred Hutchinson Group exam-
ned a regimen of Bu 12 mg/kg, melphalan 100 mg/
2, and thiotepa 500 mg/m2 in 92 patients with HD.
he TRM was 15% and 6-year overall survival (OS)
as 55% [12]. The purpose of the present study was to
nvestigate the long-term clinical results of the largest
eries of patients with primary refractory and relapsed
D treated with a radiation-free Bu regimen.
ETHODS
Between February 1990 and December 1998, 127
onsecutive eligible patients with HD underwent
igh-dose therapy with Bu, Cy, and etoposide
BuCyVP) followed by ASCT at The Ohio State
edical Center and the Cleveland Clinic Foundation.
he protocol was approved by the institutional review
oards at both institutions and patients provided writ-
en informed consent. The techniques for marrow
spiration and peripheral blood stem cell harvest after
he administration of human granulocyte colony-stim-
lating factor with chemotherapy, cryopreservation,
hawing, and infusion have been described previously
23-25].
HD was classiﬁed according to the Rye his-
opathologic classiﬁcation [26]. All patients were re-
uired to have adequate cardiac, renal, and hepatic
unctions.
reparative Regimen
The regimen was administered as previously de-
cribed [20]. Brieﬂy, Bu was administered at a dose of
mg/kg orally every 6 hours for 14 doses beginning 8
ays before stem cell infusion. Etoposide 50-60 mg/kg
as initiated 2 hours after the last dose of Bu as a
6-hour continuous intravenous infusion. Then Cy 60
g/kg was administered intravenously on 2 consecu-
ive days. Bone marrow and peripheral blood stem
ells were infused 2 days after the completion of Cy.
henytoin was given prophylactically for the preven-
ion of seizures before and during Bu administration.
u levels were not measured. Granulocyte colony-
timulating factor 5 g/kg was administered daily af-
er transplantation until the neutrophil count reached
.5  109/L. Prophylactic systemic antibiotics were
dministered when the absolute neutrophil count was c0.5  109/L and were discontinued after neutrophil
ngraftment when counts recovered to an absolute
eutrophil count 0.5  109/L.
tatistical Analysis
A partial remission required at least a 50% de-
rease in the tumor size measured by the sum of the
roducts of the perpendicular diameter of all areas of
nown disease. No response was deﬁned as less than a
0% decrease in tumor size. A complete remission was
eﬁned as no evidence of residual lymph node en-
argement by computed tomographic scan. Progres-
ive disease was deﬁned as an increase in size of any
rea of known disease or the appearance of new dis-
ase. Relapse was deﬁned as a recurrence 6 months
fter the completion of initial chemotherapy. A sensi-
ive relapse was deﬁned as at least a partial response to
alvage therapy immediately before transplantation.
atients were considered to have refractory disease if
hey progressed through their initial chemotherapy
egimen or if their disease showed less than a partial
esponse to salvage chemotherapy before transplanta-
ion.
Overall survival (OS) was measured from the time
f transplantation until death regardless of cause, with
ensoring for patients alive. The cumulative incidence
f relapse or progression was calculated from the time
f transplantation until relapse or death, except that
eath in remission was regarded as a competing risk.
nivariate analyses of survival and event-free survival
sed the Kaplan-Meier product limit method with
og-rank tests of survival curves [27]. To study the
ndependent effect of the preparative regimen and
ontrol for other baseline clinical factors such as num-
er of previous treatments, age, presence of bulky
isease (10 cm) at the time of diagnosis, B symptoms
t the time of diagnosis, and lactate dehydrogenase at
he time of transplantation, and bone marrow involve-
ent at the time of transplant, a Cox proportional
azards model was constructed for OS [28]. For all
nalysis, a 2-sided P value .05 was considered statis-
ically signiﬁcant.
ESULTS
atient Characteristics
The baseline patient characteristics are presented
n Table 1. There were 91 men and 36 women in this
tudy. The median age was 33 years (range, 14-67
ears). Seventy one percent of patients had responsive
isease, and 13% had bulky disease (10 cm). Ninety
atients were in complete or partial remission and 37
ere refractory to their last therapy at the time of
ransplantation. Most patients (76%) had 3 prior
hemotherapy regimens.
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Long-term Outcome of Busulfan-based Treatment for HD 1345verall Survival/Progression-free Survival
With a median follow-up of 6.7 years (range, 3.5-
0.2 years), the 5-year PFS was 48% (95% conﬁdence
nterval, 38%-58%; Figure 1) and the 5-year OS was
1% (95% conﬁdence interval, 42%-60%; Figure 2).
he median OS was 5.7 years and the median PFS was
.9 years. Of 20 patients alive and in remission beyond
years, only 2 patients died of late relapse at 5.1 and
.8 years.
rognostic Factors
A Cox proportional hazards model identiﬁed re-
ractory disease at time of transplantation (hazard ra-
io, 2.0; 95% conﬁdence interval, 1.5%-2.6%; P 
007) as the only signiﬁcant factor affecting relapse,
able 1. Patient Characteristics
Characteristics Patients
ge (years)
Median 33
Range 14-67
Male/Female 91/36
emission status at diagnosis
Responsive (CR/PR) 90 (71%)
Refractory 37 (29%)
umber of prior regimens
1-2 Regimens 96 (76%)
>3 Regimens 31 (24%)
tem cell source
Bone marrow 41 (32%)
PBSC 86 (68%)
argest disease bulk
<10cm 111 (87%)
>10 cm 16 (13%)
DH at time of transplant
Normal 48 (38%)
Elevated 79 (62%)
rior radiation therapy
None 60 (47%)
Prior RT 67 (53%)
DH, Lactate dehydrogenase; PBSC, peripheral blood stem cells.
Years post-transplantation
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igure 1. PFS of all patients (n  127) with HD who received
u/Cy/VP16 preparative regimen. ihereas disease bulk 10 cm (hazard ratio, 2.9; 95%
onﬁdence interval, 2.2%-3.5%; P .002) and refrac-
ory disease (hazard ratio, 1.9; 95% conﬁdence inter-
al, 1.4%-2.4%; P  .014) at time of transplantation
ere signiﬁcant factors affecting OS (Figure 3). There
Years post-transplantation
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igure 2. OS of all patients (n  127) with HD who received
u/Cy/VP16 preparative regimens.
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Remission (CR/PR)
Refractory
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B
Years post-transplantation
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Bulk >10 cm
Bulk<10 cm
igure 3. Cox multivariate regression analyses showing (A) a sig-
iﬁcant difference in remission status on OS and (B) a statistically
igniﬁcant difference in the presence of bulky disease on OS. CR
ndicates complete remission; PR, partial remission.
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N. Wadehra et al.1346as no statistically signiﬁcant inﬂuence of age, bone
arrow involvement, lactate dehydrogenase, or num-
er of chemotherapy regimens used before transplan-
ation (Table 2).
egimen-related Toxicity
The regimen was well tolerated, with 5.5% TRM
t 100 days after transplantation. Three patients died
ithin the ﬁrst 30 days. There were a total of 7
atients who had a TRM by day 100. Hepatic toxicity
as the most common life-threatening toxicity and
as the cause of death in 4 patients. All 3 patients who
ied from interstitial pneumonitis had received radia-
ion during their treatment.
The long-term toxicity of this regimen was analyzed.
hree patients developed myelodysplasia (MDS) or
cute myeloid leukemia (AML) at 1.9, 4.1, and 5.7 years
fter transplantation. All 3 patients eventually died of
ML. One patient developed transitional cell bladder
arcinoma 4 months after transplantation. Overall the
-year actuarial risk of secondary malignancy was 9%
Figure 4). One patient died of long-term pulmonary
omplications from the transplantation.
ISCUSSION
Several preparative regimens in HD with or without
BI have been investigated, with no clear superiority in
art because many of the studies have been small
10,11,29]. A higher incidence of secondarymalignancies
as been observed after TBI-containing regimens (up to
0%) compared with high-dose chemotherapy regimens
30,31]. As a consequence, several radiation-free condi-
ioning regimens have been investigated, including,
igh-dose Cy, carmustine, etoposide (CBV); carmustine,
toposide, cytarabine and melphalan (BEAM); and
CNU, etoposide, cytarabine and Cy (BEAC) [31-35].
lthough Bu preparative regimens are commonly used,
here are few published data evaluating the efﬁcacy and
olerability of Bu-based regimens.
We analyzed our experience with the novel regi-
en of Bu 14 mg/kg, Cy 120 mg/kg, and etoposide
able 2. Multivariate Analysis of Relapse Rate and Overall
urvival (OS)
Factor
P Value
Relapse Rate P Value OS
ulky disease NS P  0.002
efractory disease P  0.007 P  0.014
ge NS NS
DH > normal NS NS
ex NS NS
umber of prior regimens NS NS
tem cell source NS NS
S, nonsigniﬁcant.0-60 mg/kg in patients with HD. This regimen wielded favorable results in patients with NHL [20].
he present patient population was heavily pre-
reated, with most having received radiation and 24%
eceiving 3 prior chemotherapy regimens. Despite
his, there was a low rate of relapse and 5-year PFS
nd OS were a 48  5% and 51  5%, respectively.
imilar results have been reported after therapy with
ther non-Bu, radiation-free regimens, although only
small number of patients with HD was treated
31,34,35]. In addition, our results compare favorably
o other Bu preparative regimen studies that had a subset
f patients with HD [12,21,36]. A German group treated
0 patients with HD with Bu (16 mg/kg), Cy (120
g/kg), and VP16 (30-45 mg/kg) followed by ASCT
nd reported an 80% 3-year OS and a 67% event-free
urvival [21]. In addition, the Hutchinson Cancer Re-
earch Center treated 50 patients with HD with Bu 12
g/kg, melphalan 100 mg/m2, and thiotepa 500 mg/m2
ollowed by ASCT and found 55% and 51% 5-year
S and event-free survival, respectively [12,37].
owever, this regimen was associated with a rela-
ively high TRM of 15% [12].
The present study also validates that the addition
f etoposide to Bu and Cy is well tolerated [17,18,38].
revious groups have used higher doses of Bu by
educing the dose of VP16 [17-19, 21]. Speciﬁcally,
he TRM of 5.5% is comparable to other reported
bservations in this patient population [4,7,8,39-41].
epatic toxicity remained the most common life-
hreatening toxicity, causing the death of 4 patients.
arenteral Bu or blood level monitoring could further
educe the regimen’s hepatic toxicity, possibly by lim-
ting hepatic exposure to Bu by providing superior
osing accuracy [42]. In addition, 3 patients who re-
eived prior radiation therapy died from interstitial
neumonitis [43]. Further, improved supportive care
ince the time of the study could potentially reduce
oxicities, including the use of palifermin (recombi-
ant human keratinocyte growth factor), which has
een shown to reduce grade 3 or 4 oral mucositis [44].
Secondary Malignancies
Years post-transplantation
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igure 4. Overall 8-year actuarial risk for a secondary malignancy
as 9%.
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Long-term Outcome of Busulfan-based Treatment for HD 1347In this study active disease at the time of trans-
lantation and bulky disease had a signiﬁcant adverse
nﬂuence on OS and PFS after transplantation. Sev-
ral groups have similarly found that disease status at
he time of transplantation is an important prognostic
actor [11,31,34,39,45,46]. Bulky disease at the time of
ransplantation was also an adverse factor predicting
igher risk of relapse, which has been seen in previous
tudies [39,47].
Due to the long follow-up, the rate of late com-
lications and secondary malignancies could be char-
cterized. Three patients (2.3%) developed MDS/
ML and 1 patient acquired a solid cancer with an
-year follow-up [20,48]. The outcome for treatment-
elated MDS/AML is poor, with an median survival of
months and a 5-year survival of 0%-8% even after
llogeneic bone marrow transplantation [49,50]. Our
revious experience has shown that the incidence of
DS/AML is relatively low with Bu preparative reg-
mens. In our study of 342 patients with NHL, only 4
atients (1.2%) developed AML or MDS 1-5 years
fter transplantation [20]. The relative contribution of
reparative regimens containing TBI versus previous
lkylating/topoisomerase II chemotherapy is still not
ully known [31]. The European Bone Marrow Trans-
lantation Group and Autologous Bone Marrow
ransplant Registry have shown a low rate of MDS
fter transplantation with TBI regimens [7,8]. Several
tudies have concluded that the intensity of prior che-
otherapy may be the genesis of MDS/AML after
ransplantation [51]. However, single-institution stud-
es have shown an increased rate of MDS/AML with
adiation-containing regimens [52-55]. In particular,
reatment-associated MDS and AML is seen as a rel-
tively frequent complication (up to 20%) and lethal
ate complication, especially in TBI-containing regi-
ens [55-57].
In summary, the novel regimen of Bu 14 mg/kg,
toposide 50-60 mg/kg, and Cy 120 mg/kg is a well-
olerated and active preparative regimen for autolo-
ous transplantation in patients with HD. It is asso-
iated with a low incidence of early and late TRM and
low incidence of secondary malignancy and MDS.
ased on this large set of patients with long-term
ollow-up, it appears that the novel Bu-based prepar-
tive regimen, which also includes high-dose Cy and
toposide, is an effective and well-tolerated regimen in
D. Although promising, the deﬁnition of the opti-
al regimen in patients with HD will require prospec-
ive evaluation with other commonly used regimens.
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